Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             93 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia Zhu, Dan-Xia
 2011
 35 Supplement 1 p. 730-734
5 p.
 artikel
2 1 A mouse model highlights a role for p53 in 5q− syndrome Barlow, J.L.
 2011
 35 Supplement 1 p. S1-
1 p.
 artikel
3 Antibody-targeted horseradish peroxidase associated with indole-3-acetic acid induces apoptosis in vitro in hematological malignancies Dalmazzo, Leandro F.F.
 2011
 35 Supplement 1 p. 657-662
6 p.
 artikel
4 250 Are Fli1, EKLF, PU.1, HDM2 and TP53 factors implicated in refractory anemia and megakaryopoiesis in 5q- syndrome? Neuwirtova, R.
 2011
 35 Supplement 1 p. S98-
1 p.
 artikel
5 A report about treatment refusal and abandonment in children with acute lymphoblastic leukemia in China, 1997–2007 Wang, Yan-rong
 2011
 35 Supplement 1 p. 1628-1631
4 p.
 artikel
6 178 A retrospective analysis of responses to decitabine in therapy-related MDS patients Klimek, V.M.
 2011
 35 Supplement 1 p. S70-
1 p.
 artikel
7 216 Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study Fill, C.
 2011
 35 Supplement 1 p. S84-S85
2 p.
 artikel
8 161 Azacytidine 75mg/m2 ×5 day in high-risk myelodysplastic syndromes and acute myeloid leukemia refractory/relapsed patients: Results from a single centre Bergua, J.
 2011
 35 Supplement 1 p. S63-
1 p.
 artikel
9 7-b, a novel amonafide analogue, cause growth inhibition and apoptosis in Raji cells via a ROS-mediated mitochondrial pathway Lin, Bing
 2011
 35 Supplement 1 p. 646-656
11 p.
 artikel
10 202 B7-H1+ blasts in myelodysplastic syndromes: Morphological and genetic features and association with patient characteristics Kondo, A.
 2011
 35 Supplement 1 p. S79-
1 p.
 artikel
11 Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells Zhou, Gui-Sheng
 2011
 35 Supplement 1 p. 214-218
5 p.
 artikel
12 CDDO-Im is a stimulator of megakaryocytic differentiation Petronelli, Alessia
 2011
 35 Supplement 1 p. 534-544
11 p.
 artikel
13 Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment Terry, Emily N.
 2011
 35 Supplement 1 p. 831-833
3 p.
 artikel
14 226 Clinical analysis of 22 patients with non-del (5q) low- and intermediate-1-risk myelodysplastic syndrome treated with lenalidomide Yang, Y.
 2011
 35 Supplement 1 p. S89-
1 p.
 artikel
15 86 Clinical and prognostic relevance of isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations in myelodysplastic syndrome Chen, T.C.
 2011
 35 Supplement 1 p. S32-S33
2 p.
 artikel
16 Clinical usefulness of plasma specimens for detection of nucleophosmin 1 gene mutations in patients with normal karyotype acute myeloid leukemia Park, Sang Hyuk
 2011
 35 Supplement 1 p. e159-e160
nvt p.
 artikel
17 Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma de Brito, Luis R.
 2011
 35 Supplement 1 p. 1233-1240
8 p.
 artikel
18 99 Correlation between serum ferritin level at diagnosis and survival in lower risk, non-transfusion dependent, MDS patients Park, S.
 2011
 35 Supplement 1 p. S37-S38
2 p.
 artikel
19 Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription Manohar, Sonal M.
 2011
 35 Supplement 1 p. 821-830
10 p.
 artikel
20 175 Czech MDS Group experience with azacitidine in treatment of high risk MDS and AML patients Jonasova, A.
 2011
 35 Supplement 1 p. S68-S69
2 p.
 artikel
21 339 Deferasirox treatment in myelodysplastic syndromes: “Real-life” efficacy and safety in a single institution patient population Breccia, M.
 2011
 35 Supplement 1 p. S136-
1 p.
 artikel
22 89 Diagnosis and management of Irish patients with myelodysplastic syndrome: data from the Irish National MDS Registry Enright, H.
 2011
 35 Supplement 1 p. S34-
1 p.
 artikel
23 Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF Smith, B. Douglas
 2011
 35 Supplement 1 p. 87-94
8 p.
 artikel
24 Dimethyl sulfoxide activates tumor necrosis factorα-p53 mediated apoptosis and down regulates d-fructose-6-phosphate-2-kinase and lactate dehydrogenase-5 in Dalton's lymphoma in vivo Koiri, Raj K.
 2011
 35 Supplement 1 p. 950-956
7 p.
 artikel
25 367 Durable response after lenalidomide discontinuation in del(5q) low risk MDS Comont, T.
 2011
 35 Supplement 1 p. S147-
1 p.
 artikel
26 Early and mature endothelial progenitors and VEGFR2+-cells in multiple myeloma: Association with disease characteristics and variation in different cell compartments Udi, Josefina
 2011
 35 Supplement 1 p. 1265-1268
4 p.
 artikel
27 353 Effect of deferasirox on haemopoietic progenitor cells Vlachaki, E.
 2011
 35 Supplement 1 p. S141-S142
2 p.
 artikel
28 Effects of exogenous agmatine in human leukemia HMC-1 and HL-60 cells on proliferation, polyamine metabolism and cell cycle Haenisch, Britta
 2011
 35 Supplement 1 p. 1248-1253
6 p.
 artikel
29 Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: Induction of IL-10 expression in the stromal layers Lazarini, Mariana
 2011
 35 Supplement 1 p. 1102-1107
6 p.
 artikel
30 Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma Zimmerman, Bevin
 2011
 35 Supplement 1 p. 1491-1497
7 p.
 artikel
31 144 Epidemiology of myelodysplastic syndromes in the Republic of Armenia Daghbashyan, S.
 2011
 35 Supplement 1 p. S56-
1 p.
 artikel
32 Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes Alimena, Giuliana
 2011
 35 Supplement 1 p. 504-507
4 p.
 artikel
33 Erythropoietin activates telomerase through transcriptional and posttranscriptional regulation in human erythroleukemic JAS-REN-A cells Akiyama, Masaharu
 2011
 35 Supplement 1 p. 416-418
3 p.
 artikel
34 337 Erythropoietin in patients with myelodysplastic syndrome of refractory anemia and refractory anemia with excess blasts-1 subtypes; efficacy and prognostic factors Bartzoudis, D.
 2011
 35 Supplement 1 p. S135-
1 p.
 artikel
35 308 Erythropoietin levels: More than just a marker of ESA response? Lee, C.D.
 2011
 35 Supplement 1 p. S121-
1 p.
 artikel
36 Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients Breccia, Massimo
 2011
 35 Supplement 1 p. 159-162
4 p.
 artikel
37 Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma Evans, Robert P.
 2011
 35 Supplement 1 p. 1637-1643
7 p.
 artikel
38 Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS Park, S.
 2011
 35 Supplement 1 p. 1530-1533
4 p.
 artikel
39 113 Flow cytometric analysis of erythropoiesis: The last major frontier Cutler, J.A.
 2011
 35 Supplement 1 p. S43-S44
2 p.
 artikel
40 Genetic disruption of the scaffolding protein, Kinase Suppressor of Ras 1 (KSR1), differentially regulates GM-CSF-stimulated hyperproliferation in hematopoietic progenitors expressing activating PTPN11 mutants D61Y and E76K Yang, Zhenyun
 2011
 35 Supplement 1 p. 961-964
4 p.
 artikel
41 264 Genomic imbalances in 73 patients with MDS and complex karyotypes Zemanova, Z.
 2011
 35 Supplement 1 p. S104-
1 p.
 artikel
42 10 Guidelines for immunosuppression in MDS Epling-Burnette, P.
 2011
 35 Supplement 1 p. S4-
1 p.
 artikel
43 Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor Yu, Wenjuan
 2011
 35 Supplement 1 p. 1212-1218
7 p.
 artikel
44 Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: A single institutional experience and literature review Liu, Jane Jijun
 2011
 35 Supplement 1 p. 1571-1577
7 p.
 artikel
45 Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia Deeb, George
 2011
 35 Supplement 1 p. 579-584
6 p.
 artikel
46 233 IER3 in childhood myelodysplastic syndrome de Vries, A.
 2011
 35 Supplement 1 p. S92-
1 p.
 artikel
47 55 Independent validation of the MDS Comorbidity Score (MDS-CI) Zipperer, E.
 2011
 35 Supplement 1 p. S20-
1 p.
 artikel
48 Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition Singh, Anjali
 2011
 35 Supplement 1 p. 1649-1657
9 p.
 artikel
49 Inhibiting HDACs in a preclinical model of HTLV-1-induced adult T-cell lymphoma Harrod, Robert
 2011
 35 Supplement 1 p. 1436-1437
2 p.
 artikel
50 58 Interaction of karyotype complexity and response on overall survival and AML progression in lenalidomide-treated Low/INT-1 risk del (5q) MDS patients Giagounidis, A.
 2011
 35 Supplement 1 p. S21-
1 p.
 artikel
51 In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells Gupta, Anukriti
 2011
 35 Supplement 1 p. 1498-1505
8 p.
 artikel
52 Involvement of osteopontin and its signaling molecule CD44 in clinicopathological features of adult T cell leukemia Chagan-Yasutan, Haorile
 2011
 35 Supplement 1 p. 1484-1490
7 p.
 artikel
53 219 Long-term outcome of anemic non del 5q lower-risk MDS refractory to or relapsing after erythropoiesis stimulating agents (ESAs) Kelaidi, C.
 2011
 35 Supplement 1 p. S86-
1 p.
 artikel
54 7 Management of 1000 patients with low- and intermediate-1 risk myelodysplastic syndromes in the European LeukemiaNet MDS Registry de Swart, L.
 2011
 35 Supplement 1 p. S3-
1 p.
 artikel
55 269 Mechanisms of action of lenalidomide on erythroblastic islands in patients with low- or intermediate-1-risk MDS with del(5q) chromosome abnormality Buesche, G.
 2011
 35 Supplement 1 p. S106-
1 p.
 artikel
56 247 miRNA expression profiling in 5q- syndrome patients treated with lenalidomide Krejcik, Z.
 2011
 35 Supplement 1 p. S97-
1 p.
 artikel
57 370 Myelodysplastic syndromes in children – Bosnian aspects Bajraktarevic, A.
 2011
 35 Supplement 1 p. S147-S148
2 p.
 artikel
58 24 New prognostic scores Malcovati, L.
 2011
 35 Supplement 1 p. S9-
1 p.
 artikel
59 Novel multiplex bead-based assay with LNA-modified probes for detection of MPL exon 10 mutations Ivanova, Milena I.
 2011
 35 Supplement 1 p. 1120-1123
4 p.
 artikel
60 221 Occurrence of trisomy 8 (+8) in patients with Low- or Int-1-risk MDS with deletion 5q [del(5q)] treated with lenalidomide Mufti, G.
 2011
 35 Supplement 1 p. S87-
1 p.
 artikel
61 Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience Arcaini, Luca
 2011
 35 Supplement 1 p. 712-714
3 p.
 artikel
62 Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia Ishikawa, Yuichi
 2011
 35 Supplement 1 p. 685-688
4 p.
 artikel
63 41 Profiling and characterizing aberrant DNA and histone methylations of lineage-determining factor encoding genes RUNX1, SPIB and SPI1 in myelodysplastic syndrome Cheng, J.X.
 2011
 35 Supplement 1 p. S14-S15
2 p.
 artikel
64 Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia Xu, Wei
 2011
 35 Supplement 1 p. 1060-1065
6 p.
 artikel
65 PTPIP51 is phosphorylated by Lyn and c-Src kinases lacking dephosphorylation by PTP1B in acute myeloid leukemia Brobeil, Alexander
 2011
 35 Supplement 1 p. 1367-1375
9 p.
 artikel
66 Race and intensity of post-remission therapy in acute myeloid leukemia Brady, Anna K.
 2011
 35 Supplement 1 p. 346-350
5 p.
 artikel
67 Rac-1 GTPase controls the capacity of human leukaemic lymphoblasts to migrate on fibronectin in response to SDF-1α (CXCL12) Freret, Manuel
 2011
 35 Supplement 1 p. 971-973
3 p.
 artikel
68 Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: Impact on lymphocyte compartment composition van Tilburg, Cornelis M.
 2011
 35 Supplement 1 p. 484-491
8 p.
 artikel
69 72 Refractory Cytopenia with Multilineage Dysplasia (RCMD) patients are related to an abnormal angiogenesis del Rey, M.
 2011
 35 Supplement 1 p. S28-
1 p.
 artikel
70 192 Response to 5-azacytidine in therapy-related malignant neoplasms (t-MN) Voso, M.T.
 2011
 35 Supplement 1 p. S76-
1 p.
 artikel
71 Retraction notice to “Curcumin suppresses constitutive activation of AP-1 by downregulation of JunD protein in HTLV-1-infected T-cell lines” [Leuk. Res. 30 (2006) 313–321] Tomita, Mariko
 2011
 35 Supplement 1 p. 1130-
1 p.
 artikel
72 336 α-rHuEPO (40,000 IU twice/week) as single agent in low/intermediate risk myelodysplastic syndromes: A retrospective investigation on 113 patients Azzarà, A.
 2011
 35 Supplement 1 p. S134-S135
2 p.
 artikel
73 Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells Nishioka, Chie
 2011
 35 Supplement 1 p. 932-939
8 p.
 artikel
74 Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients Zhang, Yiqun
 2011
 35 Supplement 1 p. 1301-1306
6 p.
 artikel
75 127 Spectral karyotyping (SKY) reveals a new subset of MDS patients with clonal chromosomal abnormalities not detected by G-banding analysis Oliveira, F.M.
 2011
 35 Supplement 1 p. S49-
1 p.
 artikel
76 130 SPR chip for MDS diagnosis based on protein-protein interaction Pimkova, K.
 2011
 35 Supplement 1 p. S50-
1 p.
 artikel
77 281 Ten years of a prospective haematological survey of patients affected by Shwachman-Diamond syndrome: Results of an Italian multicentric study Sainati, L.
 2011
 35 Supplement 1 p. S110-S111
2 p.
 artikel
78 305 TET2 and IDH1/2 mutations in secondary acute myeloid leukemias: A French retrospective study Kosmider, O.
 2011
 35 Supplement 1 p. S120-
1 p.
 artikel
79 322 TET2 mutations, methylation profile and prognosis in higher risk myelodysplastic syndromes (MDS) treated with 5-azacytidine and valproic acid Voso, M.T.
 2011
 35 Supplement 1 p. S129-
1 p.
 artikel
80 The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: A meta-analysis Wang, Hao
 2011
 35 Supplement 1 p. 1170-1177
8 p.
 artikel
81 The expression of IgM is helpful in the differentiation of primary cutaneous diffuse large B cell lymphoma and follicle center lymphoma Demirkesen, Cuyan
 2011
 35 Supplement 1 p. 1269-1272
4 p.
 artikel
82 The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity Nakaya, Aya
 2011
 35 Supplement 1 p. 243-249
7 p.
 artikel
83 The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo Sanchez, Eric
 2011
 35 Supplement 1 p. 373-379
7 p.
 artikel
84 The immune reconstitution after an allogeneic stem cell transplant correlates with the risk of graft-versus-host disease and cytomegalovirus infection Torelli, Giovanni F.
 2011
 35 Supplement 1 p. 1124-1126
3 p.
 artikel
85 301 Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and Intermediate-1) Jonasova, A.
 2011
 35 Supplement 1 p. S119-
1 p.
 artikel
86 51 Transcription Intermediary Factor 1 gamma (TIF1γ) is an epigenetically-regulated tumor suppressor gene in human chronic myelomonocytic leukemia Droin, N.
 2011
 35 Supplement 1 p. S18-
1 p.
 artikel
87 Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience Le Bras, Fabien
 2011
 35 Supplement 1 p. 1444-1448
5 p.
 artikel
88 Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL) Uhrmacher, Sabrina
 2011
 35 Supplement 1 p. 1360-1366
7 p.
 artikel
89 Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis Rauw, J.
 2011
 35 Supplement 1 p. 1335-1338
4 p.
 artikel
90 295 Validation of the WHO 2008 classification for ‘non-blastic’ myelodysplastic syndromes. Lumping or splitting? Germing, U.
 2011
 35 Supplement 1 p. S116-
1 p.
 artikel
91 Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes Balleari, Enrico
 2011
 35 Supplement 1 p. 1472-1476
5 p.
 artikel
92 What are RBC-transfusion-dependence and -independence? Gale, R.P.
 2011
 35 Supplement 1 p. 8-11
4 p.
 artikel
93 Wilms’ tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood Krishnadas, Deepa K.
 2011
 35 Supplement 1 p. 1520-1526
7 p.
 artikel
                             93 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland